PO.TB09.02 · 肿瘤生物学

在正常子宫内膜中鉴定子宫内膜异位症相关卵巢癌的克隆起源

Identification of the clonal origin of endometriosis-associated ovarian cancer in normal endometrium

海报缩略图:在正常子宫内膜中鉴定子宫内膜异位症相关卵巢癌的克隆起源
编号 3529 展板 5 时间 4/20 02:00–05:00 区域 Section 33 主讲 Koichi Watanabe, MD
分会场 Tumor Evolution
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Koichi Watanabe, Nobuyuki Kakiuchi, Kosuke Ieiri, Hirona Maeda, Tomonori Hirano, Mana Taki, Koji Yamanoi, Ryusuke Murakami, Masaki Mandai, Seishi Ogawa

Kyoto University, Kyoto, Japan

摘要 Abstract

中文摘要
[引言]近期研究揭示,在包括子宫内膜在内的许多正常组织中,癌症相关基因存在广泛突变。子宫内膜异位症相关卵巢癌(EAOC)被假设起源于自子宫内膜播散至卵巢的子宫内膜异位病灶,但支持这一起源的直接证据一直缺乏。本研究旨在通过检测EAOC肿瘤与子宫内膜克隆之间共享的体细胞突变,鉴定EAOC在子宫内膜中的克隆起源。 [方法]我们对6例确诊为EAOC患者的组织学正常子宫内膜组织进行了高密度取样(每例5-32个样本,共84个样本),并开展全外显子组测序。所得的体细胞突变谱与来自同一患者的配对EAOC肿瘤进行比较。 [结果]子宫内膜样本携带的体细胞突变中位数为28.5个(范围6-74)。在84个组织学正常的子宫内膜样本中,有78个(93%)鉴定出一个或多个已知驱动基因突变,涉及PIK3CA、PIK3R1、KRAS、PPP2R1A、ARHGAP35和FBXW7,平均每个样本2.4个突变(范围0-7)。PIK3CA突变最为常见,在84个样本中的44个(52%)中检出,其次为ARHGAP35突变(25/84,30%)。值得注意的是,在两个病例中,我们鉴定出与EAOC肿瘤共享多个体细胞突变的子宫内膜样本。在病例1(74岁,卵巢透明细胞癌)中,32个子宫内膜样本中的一个与肿瘤共享16个突变,包括PTEN、PIK3CA和KRAS的改变。在病例2(31岁,双侧卵巢子宫内膜样癌)中,6个子宫内膜样本中的一个与肿瘤共享11个突变,包括PIK3CA、AKT1、PPP2R1A和CTNNB1。利用全基因组测序进行的系统发育分析估计,在两个病例中,癌症的最近共同祖先与正常子宫内膜克隆的分化均发生在患者20岁出头时。在病例1中,肿瘤获得了子宫内膜祖先中不存在的额外拷贝数改变,提示其在癌变中的潜在作用。相比之下,在病例2中,祖先子宫内膜克隆与卵巢肿瘤之间未检出明显的遗传学差异,提示从正常组织到癌症的转变可能由非遗传性事件驱动。 [结论]我们证明至少部分EAOC肿瘤起源于组织学正常子宫内膜中的一个祖先克隆。该祖先克隆已获得多个促进癌变的驱动事件。我们的发现为EAOC发生的早期事件提供了新的见解。
查看英文原文 English abstract
[Introduction]Recent studies have revealed pervasive mutations in cancer-related genes within many normal tissues, including the endometrium. Endometriosis-associated ovarian cancer (EAOC) is hypothesized to arise from endometriotic lesions seeded from the endometrium to the ovary, although direct evidence supporting this origin has been lacking. This study aimed to identify the clonal origin of EAOC in the endometrium by detecting shared somatic mutations between EAOC tumors and endometrial clones. [Methods]We performed high-density sampling of histologically normal endometrial tissues from 6 patients diagnosed with EAOC (5-32 sample/patient, 84 samples in total) and conducted whole-exome sequencing. The resulting somatic mutation profiles were compared with those of the matched EAOC tumors from the same patients. [Results]Endometrial samples harbored a median of 28.5 (range 6-74) somatic mutations. In 78 of 84 histologically normal endometrial samples (93%), one or more of known driver gene mutations involving PIK3CA, PIK3R1, KRAS, PPP2R1A, ARHGAP35 and FBXW7 were identified, with an average of 2.4 mutations/sample (range 0-7). PIK3CA mutations were the most common, detected in 44 of 84 samples (52%), followed by ARHGAP35 mutations (25/84, 30%). Notably, in two cases, we identified an endometrial sample sharing multiple somatic mutations with the EAOC tumors. In Case 1 (74 y/o, ovarian clear cell carcinoma), one of 32 endometrial samples shared 16 mutations with the tumor, including alterations in PTEN , PIK3CA , and KRAS . In Case 2 (31 y/o, bilateral ovarian endometrioid carcinoma), one of 6 endometrial samples shared 11 mutations with the tumor, including in PIK3CA, AKT1, PPP2R1A and CTNNB1 . Phylogenetic analysis using whole-genome sequencing estimated that the most recent common ancestor of the cancer diverged from the normal endometrial clone in their early 20s in both cases. In Case 1, the tumor acquired additional copy number alterations not present in the endometrial ancestor, suggesting their potential role in carcinogenesis. By contrast, in Case 2 no clear genetic differences were detected between the ancestral endometrial clone and the ovarian tumor, suggesting that the transition from normal tissue to cancer may be driven by non-genetic events. [Conclusion]We demonstrated that at least some EAOC tumors originate from an ancestral clone in the histologically normal endometrium. This ancestral clone had already acquired multiple driver events contributing to carcinogenesis. Our findings provide new insights into the early events underlying EAOC development.
利益披露 Disclosure
K. Watanabe, None.. N. Kakiuchi, None.. K. Ieiri, None.. H. Maeda, None.. T. Hirano, None.. M. Taki, None.. K. Yamanoi, None.. R. Murakami, None.. M. Mandai, None. S. Ogawa, KAN Research Institute, Inc ). ChordiaTherapeutics, Inc. ). Eisai Co., Ltd. ). Asahi Genomics Co., Ltd. Stock. Sumitomo Dainippon Pharma Co., Ltd. ). Otsuka Pharmaceutical Co., Ltd. ). Nanpuh Hospital ).

← 返回 AACR 2026 检索